NewYork Presbyterian-Weill Cornell Medical Center, New York, NY, USA.
Department of Medicine, Division of Infectious Diseases, Weill Cornell Medicine, New York, NY, USA.
Nat Rev Nephrol. 2019 Aug;15(8):463-481. doi: 10.1038/s41581-019-0150-7.
The prevalence of antimicrobial resistance among many common bacterial pathogens is increasing. The emergence and global dissemination of these antibiotic-resistant bacteria (ARB) is fuelled by antibiotic selection pressure, inter-organism transmission of resistance determinants, suboptimal infection prevention practices and increasing ease and frequency of international travel, among other factors. Patients with chronic kidney disease, particularly those with end-stage renal disease who require dialysis and/or kidney transplantation, have some of the highest rates of colonization and infection with ARB worldwide. These ARB include methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus spp. and several multidrug-resistant Gram-negative organisms. Antimicrobial resistance limits treatment options and increases the risk of infection-related morbidity and mortality. Several new antibiotic agents with activity against some of the most common ARB have been developed, but resistance to these agents is already emerging and highlights the dire need for new treatment options as well as consistent implementation and improvement of basic infection prevention practices. Clinicians involved in the care of patients with renal disease must be familiar with the local epidemiology of ARB, remain vigilant for the emergence of novel resistance patterns and adhere strictly to practices proven to prevent transmission of ARB and other pathogens.
许多常见细菌病原体的抗生素耐药性的流行率正在上升。这些抗生素耐药菌(ARB)的出现和全球传播是由抗生素选择压力、耐药决定因素在生物体间的传播、感染预防措施不当以及国际旅行的便利性和频率增加等因素共同推动的。慢性肾脏病患者,尤其是需要透析和/或肾移植的终末期肾病患者,在全球范围内具有最高的 ARB 定植和感染率。这些 ARB 包括耐甲氧西林金黄色葡萄球菌、耐万古霉素肠球菌属和几种多药耐药革兰氏阴性菌。抗生素耐药性限制了治疗选择,并增加了感染相关发病率和死亡率的风险。已经开发出了几种针对一些最常见的 ARB 具有活性的新型抗生素药物,但这些药物的耐药性已经出现,这突出表明迫切需要新的治疗选择以及严格执行和改进基本感染预防措施。参与肾脏疾病患者治疗的临床医生必须熟悉当地 ARB 的流行病学,对新的耐药模式的出现保持警惕,并严格遵守已证明可预防 ARB 和其他病原体传播的实践。